Skip to main content
. Author manuscript; available in PMC: 2017 Jul 26.
Published in final edited form as: Eur J Cancer. 2013 Apr 8;49(10):2345–2355. doi: 10.1016/j.ejca.2013.03.005

Fig. 5.

Fig. 5

The P546S mutation affects NIH-3T3 cells sensitivity to cetuximab. (A) NIH-3T3 cells that stably express the P546S mutation show a dramatic increase in sensitivity to cetuximab both singly or when combined with R705G mutation (B), compared to wild type or empty vector only transfected cells. The R705G and G719S mutations do not significantly affect sensitivity to cetuximab (C). (D) Cetuximab treatment has a more profound effect on the epidermal growth factor receptor (EGFR) signalling pathway in cells expressing mutant EGFR-P546S than it did on cells expressing the wild type protein.